Company · founded 2010
SiteOne Therapeutics (United States)
Bozeman, United States · siteonetherapeutics.com
- Citations, last 5 years
- 28
- Works, last 5 years
- 2
- h-index
- 21
- Scientists listed
- 1
- Grants since 2016
- 14
Grants received
2023–2025 · cooperative agreement · UG3
Development of a Potent and Selective Nav1.8 inhibitor for the Treatment of Acute and Chronic Pain with the Goal of Reducing Opioid Use and Preventing Opioid Use Disorders
John Cureton Hunter · SiteOne Therapeutics (United States) · funded by National Institutes of Health
2021–2024 · research · R44
Development of a Selective Inhibitor of NaV1.7 for the Treatment of Ocular Pain
Sheri Denet Klas · SiteOne Therapeutics (United States) · funded by National Institutes of Health
2021–2022 · cooperative agreement · U44
Discovery of NaV1.7 Inhibitors for the Treatment of Pain
John Vincent Mulcahy · SiteOne Therapeutics (United States) · funded by National Institutes of Health
2021–2023 · research · R44
Development of a Selective Inhibitor of NaV1.7 for the Treatment of Ocular Pain
Sheri Denet Klas · SiteOne Therapeutics (United States) · funded by National Institutes of Health
2019–2023 · cooperative agreement · UG3
Development of a Potent and Highly Selective NaV1.7 Inhibitor for the Treatment of Acute Pain with the Goal of Reducing Opioid Use and Preventing Opioid Use Disorders
John Cureton Hunter · SiteOne Therapeutics (United States) · funded by National Institutes of Health
2019–2021 · research · R43
Development of NaV1.7 Inhibitors for the Treatment of Chronic Cough
John Cureton Hunter · SiteOne Therapeutics (United States) · funded by National Institutes of Health
2019–2023 · research · R44
Development of Nav1.7 Selective Inhibitors for the Treatment of Chronic Cough
John Cureton Hunter · SiteOne Therapeutics (United States) · funded by National Institutes of Health
2019–2021 · cooperative agreement · U44
Discovery of NaV1.7 Inhibitors for the Treatment of Pain
John Vincent Mulcahy · SiteOne Therapeutics (United States) · funded by National Institutes of Health
2019–2021 · cooperative agreement · UG3
Development of a Potent and Highly Selective NaV1.7 Inhibitor for the Treatment of Acute Pain with the Goal of Reducing Opioid Use and Preventing Opioid Use Disorders
John Cureton Hunter · SiteOne Therapeutics (United States) · funded by National Institutes of Health
2019–2021 · cooperative agreement · U44
Discovery of NaV1.7 Inhibitors for the Treatment of Pain
John Vincent Mulcahy · SiteOne Therapeutics (United States) · funded by National Institutes of Health
2019–2024 · research · R44
Development of Nav1.7 Selective Inhibitors for the Treatment of Chronic Cough
John Cureton Hunter · SiteOne Therapeutics (United States) · funded by National Institutes of Health
2017–2020 · grant · DMRDP
IND-Enabling Development of Selective Inhibitors of NaV1.7
John Mulcahy · SiteOne Therapeutics (United States) · funded by Congressionally Directed Medical Research Programs
2015–2021 · research · R44
GUANIDINIUM DERIVATIVES FOR THE TREATMENT OF OCULAR PAIN
Anton Delwig · SiteOne Therapeutics (United States) · funded by National Institutes of Health
2015–2020 · research · R44
GUANIDINIUM DERIVATIVES FOR THE TREATMENT OF OCULAR PAIN
Anton Delwig · SiteOne Therapeutics (United States) · funded by National Institutes of Health